Is Rexahn Pharmaceuticals Inc. (NYSE MKT:RNN) disaster in waiting?


Equity ownership in Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) is spread out. As per the latest figures, insiders own 2.50% of the company. That compares with institutional ownership of 9.60%.

In terms of transactions along the lines of equity ownership, the company has seen -3.95% insider transactions and 0.83% institutional transactions in the recent months.

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction. Longer term, the trend strength is Minimum.

Recently, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it will present preliminary data from the Phase IIa study of RX-3117 in advanced and metastatic bladder cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, which is being held June 2-6 in Chicago, Illinois.

Title: Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ib/IIa study.

Rexahn Pharmaceuticals, Inc. has 242.86M shares outstanding of which 230.21M float. The short float is 8.76%, implying a short ratio of 3.02.

In terms of stock price performance, shares of Rexahn Pharmaceuticals, Inc. have moved 912.76% over the last one week and have moved 542.39% over the last one month. Stock performance for the last one quarter is 2049.43% and for the last six months is 2459.64%. Over the last 12 months shares of Rexahn Pharmaceuticals, Inc. have moved 1352.08%% and their movement so far this year is 2697.74%.

What has Rexahn Pharmaceuticals, Inc. produced for investors over the last 12 months? The company?s financial documents reveal return on assets for the trailing 12 months is -127.60% and return on equity for the same period is -209.00%.

Where does Rexahn Pharmaceuticals, Inc. stands in terms of liquidity and balance sheet strength? The company?s current ratio for the most recent quarter is 11.30 and quick ratio for the same period is 11.30. The company?s Long Term Debt/Equity and Total Debt/Equity ratios for the most recent quarter are 0.00 and 0.00, respectively.

Other performance indicators worth keeping in mind in this stock is that its P/Cash for the most recent quarter is 52.12.

Analysts who have weighed on the stock have an average price target of $23.30 on it and average recommendation of 1.70.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.